AstraZeneca’s Strong Strategic Positioning and Growth Potential Justifies Buy Rating

Goldman Sachs analyst Rajan Sharma has maintained their bullish stance on AZN stock, giving a Buy rating on June 3.

Rajan Sharma has given his Buy rating due to a combination of factors that highlight AstraZeneca’s strong financial and strategic positioning. The company reiterated its expectation for a limited impact from potential pharmaceutical tariffs, with an assumption that tariffs would be calculated on the transfer price. This indicates a level of resilience against regulatory changes that could impact profitability.
Additionally, AstraZeneca’s management has set a goal of achieving a mid-30s percentage operating margin, which demonstrates a commitment to improving efficiency and profitability. The company also aims for $80 billion in revenue by 2030, suggesting significant growth potential. These strategic goals, alongside ongoing developments in key areas such as baxodrostat Phase 3, ESR1 mutation testing, and Enhertu, provide a strong foundation for future performance, justifying the Buy rating.

According to TipRanks, Sharma is an analyst with an average return of -4.2% and a 44.29% success rate. Sharma covers the Healthcare sector, focusing on stocks such as AstraZeneca, AstraZeneca, and GlaxoSmithKline.

In another report released on June 3, Barclays also maintained a Buy rating on the stock with a £140.00 price target.